Results 71 to 80 of about 21,216 (279)
Preferred antiretroviral drugs for the next decade of scale up [PDF]
, 2012 Global commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prevent HIV transmission.
Andrieux-Meyer, Isabelle +10 more
core +4 more sources
Open Forum Infectious Diseases, 2018 Background This study investigates the association of clinical and demographic predictors with abdominal fat gain, measured using waist circumference (WC) and self-reported abdominal size.
Priya Bhagwat +6 more
semanticscholar +1 more source
HIV Medicine, EarlyView.Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Cristina Mussini +24 more
wiley +1 more source
Journal of Antimicrobial Chemotherapy, 2019 BACKGROUND Dual therapy combining integrase inhibitors and NNRTIs represents a promising regimen in ageing HIV-infected individuals with long exposure to nucleoside analogues and PIs.
C. Katlama +17 more
semanticscholar +1 more source
HIV Medicine, EarlyView.Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito +13 more
wiley +1 more source
Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir [PDF]
, 2014 There are few clinical data on the combination abacavir/lamivudine plus raltegravir. We compared the outcomes of patients from the SPIRAL trial receiving either abacavir/lamivudine or tenofovir/emtricitabine at baseline who had taken at least one dose of
D'Albuquerque, Polyana M. +4 more
core +2 more sources
HIV Medicine, Volume 27, Issue 1, Page 86-95, January 2026.Abstract Objectives Alterations in lipids and apolipoproteins contribute to cardiovascular disease (CVD) and are common in people with HIV. The aim of our study was to compare lipid profiles and body composition between people with and without HIV and to explore whether any associations with HIV could be explained by socio‐demographic, clinical ...
S. Savinelli +11 more
wiley +1 more source
HIV INTEGRASE INHIBITORS: THE BASIS OF EFFECTIVE AND SAFE ANTIRETROVIRAL THERAPY
Медицинский совет, 2017 The article examines the efficacy and safety of HIV integrase inhibitors (raltegravir, dolutegravir) in antiretroviral therapy (ART) regimens in various groups of HIV-infected patients: patients with high HIV RNA blood levels, patients with low CD4 ...
V. I. SHAKHGILDYAN
doaj +1 more source
Resistance to novel drug classes [PDF]
, 2009 Understanding the mechanisms that underlie resistance development to novel drugs is essential to a better clinical management of resistant viruses and to prevent further resistance development and spread. RECENT FINDINGS: Integrase inhibitors and CCR5
Calvez, V. +3 more
core +1 more source
Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025
HIV Medicine, Volume 27, Issue 1, Page 18-32, January 2026.Abstract Background The European AIDS Clinical Society (EACS) guidelines were revised for the 21st time in 2025, with updates covering all aspects of HIV care. Key Points of the Guidelines Update The structure of the guidelines has been reorganized into two parts: Part I focuses on the management and prevention of HIV and related infections, and Part ...
Juan Ambrosioni +19 more
wiley +1 more source